- Home
- KROS
as 07-01-2025 3:38pm EST
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 558.9M | IPO Year: | 2020 |
| Target Price: | $20.63 | AVG Volume (30 days): | 637.6K |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.11 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.12 - $72.37 | Next Earning Date: | 08-06-2025 |
| Revenue: | $214,713,000 | Revenue Growth: | 91657.70% |
| Revenue Growth (this year): | 5006.76% | Revenue Growth (next year): | -89.09% |
Stock Insider Trading Activity of Keros Therapeutics Inc. (KROS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC | KROS | 10% Owner | Apr 9 '25 | Buy | $9.40 | 34,925 | $328,127.36 | 3,493,404 |
Latest Keros Therapeutics Inc. News
KROS Breaking Stock News: Dive into KROS Ticker-Specific Updates for Smart Investing
TipRanks
21 days ago
McDonald’s downgraded on GLP-1 drug worries: Wall Street’s top analyst calls
Benzinga
21 days ago
Keros Therapeutics' Quiet Near-Term Outlook Overshadows Pipeline Potential: Analyst
MT Newswires
21 days ago
Keros Therapeutics Hindered by KER-065 Concerns Despite 'Intriguing' Pipeline, BofA Says
MT Newswires
22 days ago
BofA Securities Downgrades Keros Therapeutics to Neutral From Buy, Adjusts Price Target to $18 From $32
MT Newswires
22 days ago
Keros Therapeutics Shareholder Seeks $475 Million Dividend; Threatens to Nominate New Directors at 2026 Annual Meeting
PR Newswire
22 days ago
ADAR1 Issues Statement on Keros Therapeutics' Troubling 2025 Director Election Results and Insufficient Capital Return Proposal
MT Newswires
23 days ago
Keros to Return $375 Million to Shareholders Following Strategic Review
GlobeNewswire
23 days ago
Keros Announces Return of $375 Million in Excess Capital to Stockholders
Compare KROS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KROS Keros Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.